{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:10:07Z","timestamp":1789103407095,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144406"],"award-info":[{"award-number":["R01HL144406"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implementation Sci"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Recently, a 3-month (12-dose) regimen of weekly isoniazid and rifapentine (3HP) was recommended by the World Health Organization for the prevention of tuberculosis (TB) among people living with HIV (PLHIV) on common antiretroviral therapy regimens. The best approach to delivering 3HP to PLHIV remains uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We developed a three-armed randomized trial assessing optimized strategies for delivering 3HP to PLHIV. The trial will be conducted at the Mulago Immune Suppression Syndrome (i.e., HIV\/AIDS) clinic in Kampala, Uganda. We plan to recruit 1656 PLHIV, randomized 1:1 to each of the three arms (552 per arm). Using a hybrid type 3 effectiveness-implementation design, this pragmatic trial aims to (1) compare the acceptance and completion of 3HP among PLHIV under three delivery strategies: directly observed therapy (DOT), self-administered therapy (SAT), and informed patient choice of either DOT or SAT (with the assistance of a decision aid); (2) to identify processes and contextual factors that influence the acceptance and completion of 3HP under each delivery strategy; and (3) to estimate the costs and compare the cost-effectiveness of three strategies for delivering 3HP. The three delivery strategies were each optimized to address key barriers to 3HP completion using a theory-informed approach. We hypothesize that high levels of treatment acceptance and completion can be achieved among PLHIV in sub-Saharan Africa and that offering PLHIV an informed choice between the optimized DOT and SAT delivery strategies will result in greater acceptance and completion of 3HP. The design and planned evaluation of the delivery strategies were guided by the use of implementation science conceptual frameworks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>3HP\u2014one of the most promising interventions for TB prevention\u2014will not be scaled up unless it can be delivered in a patient-centered fashion. We highlight shared decision-making as a key element of our trial design and theorize that offering PLHIV an informed choice between optimized delivery strategies will facilitate the highest levels of treatment acceptance and completion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03934931\">NCT03934931<\/jats:ext-link>; Registered 2 May 2019.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13012-020-01025-8","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:03:47Z","timestamp":1597233827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda"],"prefix":"10.1186","volume":"15","author":[{"given":"Jillian L.","family":"Kadota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Nabunje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Welishe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie L.","family":"Ssemata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opira","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Katahoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Namusobya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Kamya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Katamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-7640","authenticated-orcid":false,"given":"Fred C.","family":"Semitala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"1025_CR1","unstructured":"World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland; 2011."},{"issue":"9","key":"1025_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"C Danel","year":"2015","unstructured":"Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808\u201322.","journal-title":"N Engl J Med"},{"key":"1025_CR3","unstructured":"World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019."},{"key":"1025_CR4","unstructured":"Motsamai OI, editor IPT Botswana Experience - Ministry of Health Botswana. World Health Organization: Meeting Presentation; 2011; Addis Ababa, Ethiopia."},{"key":"1025_CR5","unstructured":"World Health Organization. Report of a \u201clessons learnt\u201d workshop on the six ProTEST pilot projects in Malawi, South Africa and Zambia. Geneva, Switzerland: World Health Organization: Stop TB and HIV\/AIDS Departments; 2004."},{"issue":"2","key":"1025_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087166","volume":"9","author":"T Makanjuola","year":"2014","unstructured":"Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV\/AIDS: a systematic review of qualitative data. PLoS One. 2014;9(2):e87166.","journal-title":"PLoS One"},{"issue":"2","key":"1025_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.trstmh.2011.10.015","volume":"106","author":"PM Namuwenge","year":"2012","unstructured":"Namuwenge PM, Mukonzo JK, Kiwanuka N, Wanyenze R, Byaruhanga R, Bissell K, et al. Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg. 2012;106(2):84\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"11","key":"1025_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1025_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"23","key":"1025_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"4","key":"1025_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","volume":"69","author":"M Weiner","year":"2014","unstructured":"Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079\u201385.","journal-title":"J Antimicrob Chemother"},{"key":"1025_CR12","unstructured":"Dooley KE, Churchyard G, Savic RM, Gupte A, Marzinke MA, Zhang N, et al., editors. Safety & PK of weekly rifapentine\/isoniazid (3HP) in adults with HIV on Dolutegravir. Conference on Retroviruses and Opportunistic Infections (CROI); 2019 March 4-7, 2019; Seattle, Washington."},{"issue":"11","key":"1025_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"1025_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001018","volume":"3","author":"R Subbaraman","year":"2018","unstructured":"Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. BMJ Glob Health. 2018;3(5):e001018.","journal-title":"BMJ Glob Health"},{"issue":"10","key":"1025_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689\u201397.","journal-title":"Ann Intern Med"},{"key":"1025_CR16","doi-asserted-by":"crossref","unstructured":"Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a Medication Event Reminder Monitor System (MERM) by providers and patients to improve adherence in the management of tuberculosis. Int J Environ Res Public Health. 2017;14(10).","DOI":"10.3390\/ijerph14101115"},{"issue":"7","key":"1025_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040238","volume":"4","author":"SA Munro","year":"2007","unstructured":"Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238.","journal-title":"PLoS Med"},{"issue":"9","key":"1025_CR18","first-page":"1037","volume":"12","author":"PJ Munseri","year":"2008","unstructured":"Munseri PJ, Talbot EA, Mtei L. Fordham von Reyn C. completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008;12(9):1037\u201341.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"1025_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217\u201326.","journal-title":"Med Care"},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.","journal-title":"Implement Sci"},{"issue":"5","key":"1025_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","volume":"44","author":"C Charles","year":"1997","unstructured":"Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681\u201392.","journal-title":"Soc Sci Med"},{"issue":"10","key":"1025_CR22","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1503\/cmaj.090523","volume":"180","author":"KE Thorpe","year":"2009","unstructured":"Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ. 2009;180(10):E47\u201357.","journal-title":"CMAJ."},{"issue":"9","key":"1025_CR23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137.","journal-title":"Am J Public Health"},{"key":"1025_CR24","volume-title":"Crossing the quality chasm: a new health system for the 21st century","author":"A CoQoHCi","year":"2001","unstructured":"CoQoHCi A. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: Institute of Medicine; 2001."},{"issue":"4","key":"1025_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000126073","volume":"77","author":"EA Joosten","year":"2008","unstructured":"Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77(4):219\u201326.","journal-title":"Psychother Psychosom"},{"key":"1025_CR26","volume":"10","author":"D Stacey","year":"2011","unstructured":"Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;10:CD001431.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1025_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094670","volume":"9","author":"MA Durand","year":"2014","unstructured":"Durand MA, Carpenter L, Dolan H, Bravo P, Mann M, Bunn F, et al. Do interventions designed to support shared decision-making reduce health inequalities? A systematic review and meta-analysis. PLoS One. 2014;9(4):e94670.","journal-title":"PLoS One"},{"issue":"7","key":"1025_CR28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.socscimed.2005.02.001","volume":"61","author":"RM Epstein","year":"2005","unstructured":"Epstein RM, Franks P, Fiscella K, Shields CG, Meldrum SC, Kravitz RL, et al. Measuring patient-centered communication in patient-physician consultations: theoretical and practical issues. Soc Sci Med. 2005;61(7):1516\u201328.","journal-title":"Soc Sci Med"},{"key":"1025_CR29","unstructured":"Ergonomics of human-system interaction \u2014 part 210: human-centred design for interactive systems [Internet]. International Organization for Standardization. 2019. Available from: https:\/\/www.iso.org\/standard\/77520.html."},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"a2390","DOI":"10.1136\/bmj.a2390","volume":"337","author":"M Zwarenstein","year":"2008","unstructured":"Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390.","journal-title":"BMJ."},{"key":"1025_CR31","first-page":"7","volume":"16","author":"C Jackson","year":"2014","unstructured":"Jackson C, Eliasson L, Barber N, Weinman J. Applying COM-B to medication adherence: a suggested framework for research and interventions. Eur Health Psychol. 2014;16:7\u201317.","journal-title":"Eur Health Psychol"},{"issue":"2","key":"1025_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1025_CR33","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"1","key":"1025_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pec.2009.09.034","volume":"80","author":"L Kriston","year":"2010","unstructured":"Kriston L, Scholl I, Holzel L, Simon D, Loh A, Harter M. The 9-item shared decision making questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2010;80(1):94\u20139.","journal-title":"Patient Educ Couns"},{"key":"1025_CR35","unstructured":"Harter M, Scholl I. SDM-Q-9 \/ SDM-Q-Doc: The 9-item Shared Decision Making Questionnaire Germany: University Medical Center Hamburg-Eppendorf. Available from: http:\/\/www.patient-als-partner.de\/index.php?article_id=20&clang=2. 2010."},{"key":"1025_CR36","unstructured":"World Health Organization. Tuberculosis patient cost surveys: a handbook. Geneva: World Health Organization; 2017."},{"key":"1025_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-publhealth-031816-044215","volume":"38","author":"CH Brown","year":"2017","unstructured":"Brown CH, Curran G, Palinkas LA, Aarons GA, Wells KB, Jones L, et al. An overview of research and evaluation designs for dissemination and implementation. Annu Rev Public Health. 2017;38:1\u201322.","journal-title":"Annu Rev Public Health"},{"issue":"8","key":"1025_CR38","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/civ464","volume":"61","author":"AT Podany","year":"2015","unstructured":"Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322\u20137.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"1025_CR39","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1472-6947-13-S2-S11","volume":"13","author":"D Stacey","year":"2013","unstructured":"Stacey D, Kryworuchko J, Belkora J, Davison BJ, Durand MA, Eden KB, et al. Coaching and guidance with patient decision aids: a review of theoretical and empirical evidence. BMC Med Inform Decis Mak. 2013;13(Suppl 2):S11.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"1025_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13012-018-0731-z","volume":"13","author":"I Scholl","year":"2018","unstructured":"Scholl I, LaRussa A, Hahlweg P, Kobrin S, Elwyn G. Organizational- and system-level characteristics that influence implementation of shared decision-making and strategies to address them - a scoping review. Implement Sci. 2018;13(1):40.","journal-title":"Implement Sci"}],"container-title":["Implementation Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13012-020-01025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13012-020-01025-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13012-020-01025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T17:52:46Z","timestamp":1667757166000},"score":1,"resource":{"primary":{"URL":"https:\/\/implementationscience.biomedcentral.com\/articles\/10.1186\/s13012-020-01025-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1186\/s13012-020-01025-8","relation":{},"ISSN":["1748-5908"],"issn-type":[{"value":"1748-5908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the University of California San Francisco Committee on Human Research, the Makerere University School of Medicine Research Ethics Committee, and the Uganda National Council for Science and Technology. All participants will provide written informed consent in their preferred language (English or Luganda) to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS and DP are human-centered design consultants for The Empathy Studio. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}